AIF1 and COVID-19: Notably, COVID-19 samples (Figure 5A–D) showed a three-fold increase in the immunoreactive profile of Iba1 (3.06 ± 0.6) compared to that in the controls (1.0 ± 0.1) (Figure 5E,F) (p < 0.01).